Day 2 – Sunday, October 19

GLAUCOMA SUBSPECIALTY DAY

As more state legislatures are relaxing anti-marijuana laws, physicians are being put in the middle by patients requesting prescriptions or authorizations for its use for medical needs, said Marc F. Lieberman, MD. » Read Dr. Lieberman's analysis

CORNEA SUBSPECIALTY DAY

Evidence for assessing the efficacy and safety of anti-VEGF agents for treating corneal and ocular surface disease is accumulating. However, there is clearly a need for more research to define if, when, and how this therapy should be used, said Anat Galor, MD. » Read the evidence

A targeted approach to treatment based on the findings of a thorough history, appropriate testing, and clinical exam can be successful for bringing relief to many patients with dry eye that is difficult to manage, said Deepinder K. Dhaliwal, MD.
» Read about the alternative treatment

RETINA SUBSPECIALTY DAY

There has been considerable progress in treatment for DME in the last several years, but a look at the investigational pipeline indicates further advances are likely on the horizon, said Peter A. Campochiaro, MD. » Find out what's to come

FROM THE SHOW FLOOR

Heidelberg Engineering GmbH announces an ophthalmic picture archiving and communication system platform.
» More on the new platform

OCULUS Surgical launched ImproVue ophthalmic lubricant drops for topical use to hydrate and lubricate the outer surface of the eye. » More on the new drops